Can a Medicare Ad­van­tage in­sur­er be great at drug de­vel­op­ment for their tar­get au­di­ence?

The top team at Clover Health be­lieves they can do some­thing no oth­er health in­sur­er in the US has at­tempt­ed: Build new drugs from scratch.

The buzzy com­pa­ny run by Vivek Gari­pal­li — who’s raised hun­dreds of mil­lions of dol­lars for his new-wave in­sur­ance com­pa­ny — tapped ex-Pfiz­er ex­ec Cheng Zhang to run his new biotech start­up, Clover Ther­a­peu­tics. And now Zhang and CSO Mar­cel van der Brug have al­lied with none oth­er than Genen­tech to start putting their ex­ten­sive health­care da­ta to work with ge­net­ics ex­perts to start hunt­ing new drugs that af­flict their pop­u­la­tion of ag­ing cus­tomers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.